8 September 2022 - When drug-buying agency PHARMAC switched to a cheaper vaccine covering fewer strains of potentially deadly pneumococcal disease, the health sector was worried.
Some feared it was “a backward step” that would lead to more disease. Others fretted it would disadvantage Māori and Pacific children.
Time has proven them both right.